NCT04541108 - Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 26, 2021

Primary Completion Date

December 31, 2031

Study Completion Date

December 31, 2031

Conditions

Solid Tumor

Interventions

BIOLOGICAL

Rilvegostomig

Intratumoral microdose injection by the CIVO device.

BIOLOGICAL

Volrustomig

Intratumoral microdose injection by the CIVO device.

BIOLOGICAL

Sabestomig

Intratumoral microdose injection by the CIVO device.

BIOLOGICAL

Pembrolizumab

Intratumoral microdose injection by the CIVO device.

Trial Locations (12)

10467

RECRUITING

Montefiore Medical Center, The Bronx

19107

RECRUITING

University of Pennsylvania, Philadelphia

27157

WITHDRAWN

Wake Forest University Health Sciences, Winston-Salem

27599

RECRUITING

University of North Carolina, Chapel Hill

29406

RECRUITING

Sarah Cannon Research Institute, Charleston

30308

RECRUITING

Emory Winship Cancer Institute, Atlanta

45229

COMPLETED

UC Health, Cincinnati

71115

RECRUITING

LSU Health Sciences Center - Shreveport, Shreveport

77030

RECRUITING

UT Health, Houston

95817

RECRUITING

UC Davis, Sacramento

97239

RECRUITING

Oregon Health & Science University (OHSU), Portland

98109

RECRUITING

University of Washington, Seattle